Back to Journals » OncoTargets and Therapy » Volume 13

MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells

Authors Zhu B, Chen W, Fu Y, Cui X, Jin L, Chao J, Yun X, Gao P, Shan S, Li J, Yin X, Zhu C, Qin X

Received 30 March 2020

Accepted for publication 11 June 2020

Published 14 July 2020 Volume 2020:13 Pages 6873—6884

DOI https://doi.org/10.2147/OTT.S256153

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Leo Jen-Liang Su


Bei Zhu,1,2 Weixian Chen,2 Yue Fu,2 Xiaohan Cui,1 Lei Jin,2 Jiadeng Chao,2 Xiao Yun,1,2 Peng Gao,2,3 Shiting Shan,1,2 Jun Li,2,3 Xu Yin,1,2 Chunfu Zhu,2 Xihu Qin2

1Nanjing Medical University, Nanjing 210029, People’s Republic of China; 2Department of General Surgery, The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, Changzhou 213000, People’s Republic of China; 3Dalian Medical University, Dalian 116023, People’s Republic of China

Correspondence: Chunfu Zhu; Xihu Qin Email zcfmlm@163.com; zcfmlm@njmu.edu.cn

Aim: This study aimed to explore the regulative mechanisms of miR-27a-3p in chemo-resistance of breast cancer cells.
Materials and Methods: qRT-PCR was employed to determine miR-27a-3p expression in two breast cancer cell lines, MCF-7 and MCF-7/adriamycin-resistant cell line (MCF-7/ADR). The two cell lines were treated with miR-27a-3p mimics or inhibitors or corresponding negative control (NC), respectively. The changes were investigated by qRT-PCR, CCK-8 assay, Western blot (WB), colony formation assay, and flow cytometry assay. Moreover, luciferase reporter assay was analyzed to verify the downstream target gene of miR-27a-3p. Further investigation in the correlation between miR-27a-3p and BTG2 was launched by WB, flow cytometry assay, and CCK-8 assay. The expression of Akt and p-Akt was detected by WB.
Key Findings: Significantly higher miR-27a-3p expression was confirmed in MCF-7/ADR as compared with sensitive cell line MCF-7 (P< 0.05). The down-regulation of miR-27a-3p in MCF-7/ADR enhanced the sensitivity of cancer cells to adriamycin treatment, decreased multidrug resistance gene 1/P-glycoprotein (MDR1/P-gp) expression, enhanced the apoptosis-related proteins expression, increased adriamycin-induced apoptosis, and inhibited cell proliferation as compared to NC groups (P< 0.05). The up-regulation of miR-27a-3p in MCF-7 showed the opposite results. BTG2 is identified as a direct target of miR-27a-3p and its down-regulation reversed ADR-resistance. BTG2 treatment exhibited inhibitory effect on PI3K/Akt pathway in MCF-7/ADR cells.
Significance: miR-27a-3p might be associated with resistance of breast cancer cells to adriamycin treatments, modulating cell proliferation and apoptosis by targeting BTG2 and promoting the PI3K/Akt pathway in breast cancer cells. miR-27a-3p/BTG2 axis might be a potential therapeutic target for clinical BC resistance.

Keywords: miR-27a-3p, chemoresistance, breast cancer, adriamycin, BTG2

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]